Biological collection

Phase 3Biologic

AAssistance Publique - Hôpitaux de Paris

Biological collection is one of 273 biologic programs targeting Preeclampsia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

272

Competitors

Pipeline

Status by Indication[3][1]

Indication

PreeclampsiaActive, not recruiting

COVID-19Active, not recruiting

CachexiaActive, not recruiting

StrokeActive, not recruiting

Brain InjuryActive, not recruiting

EndometriosisActive, not recruiting

EpilepsyCompleted

ImagingActive, not recruiting

CARRecruiting

AutoimmunityActive, not recruiting

PreeclampsiaPreclinical

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

CachexiaPreclinical

Active, not recruiting

StrokePreclinical

Active, not recruiting

Brain InjuryPreclinical

Active, not recruiting

EndometriosisPreclinical

Active, not recruiting

EpilepsyPreclinical

Completed

ImagingPreclinical

Active, not recruiting

CARPreclinical

Recruiting

AutoimmunityPhase 3

Active, not recruiting

Competition

Competitive Landscape

317 competitors in COVID-19

#DrugCompanyPhaseTrials

Biological collection

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 2

Calciferol

Benadryl

1 4

Rayaldee

OOrganon and Co

Preclinical

1 5

Olokizumab

UCB

Preclinical

1 6

Other Tkis

Bayer

Preclinical

1 7

Hymecromone

SStanford University

Preclinical

1 8

Serology

UUniversity Hospital Center of Martinique

Preclinical

3 9

T89

TTasly Pharmaceuticals, Inc.

Preclinical

2 10

Pfizer-Biontech COVID-19 MRNA Vaccine

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Not yet recruiting

Preeclampsia

NCT06464159

Q2 2027

N/AActive, not recruiting

Imaging

NCT04224779

Q4 2028

Not yet recruiting

Chronic Pain

NCT07685184

Q2 2029

N/ARecruiting

Cachexia

NCT05257135

Clinical

Trials by Indication[1]

Preeclampsia1 trial

New Therapeutic Strategy Against Preeclampsia

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris··NCT06464159·100 enrolled

CAR1 trial

Development of a Clinical and Biological Database in Peritoneal Carcinosis (BCB CARCINOSE)

Recruiting·IInstitut du Cancer de Montpellier - Val d'Aurelle·N/A·NCT04221464·600 enrolled

COVID-191 trial

Clinical Characterisation Protocol for COVID-19 in People Living With HIV

Unknown status·AAssistance Publique - Hôpitaux de Paris··NCT04361604·270 enrolled

Imaging1 trial

Liquid Biopsies and IMAging for Improved Cancer Care

Active, not recruiting·IInstitut du Cancer de Montpellier - Val d'Aurelle·N/A·NCT04224779·16 enrolled

Stroke1 trial

Clinical and Biological Strokes Collection in Reunion Island

Completed·—·N/A·NCT05598138·795 enrolled

8 more indications

Brain Injury1 trial

Identification of Predictive Neuroinflammatory Biomarkers of Neuro-radiological Evolution in Severe Traumatic Brain Injury

Unknown status·AAssistance Publique - Hôpitaux de Paris·N/A·NCT03659006·80 enrolled

Endometriosis1 trial

Perinatal Consequences of Endometriosis

Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT02498691·1,444 enrolled

Autoimmunity1 trial

Patient-Reported AutoImmunity Secondary to Cancer immunothErapy

Active, not recruiting·UUniversity Hospital, Strasbourg, France·Phase 4·NCT03849131·905 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Methyl-qPCR : a New Predictive Marker for Epstein-Barr Virus-associated Lymphoproliferations During Allogeneic Hematopoietic Stem Cell Transplantation

Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT03343834·138 enrolled

Cachexia1 trial

A Clinico-biological Database in Cachexia in Patients With Colon Cancer

Recruiting·IInstitut du Cancer de Montpellier - Val d'Aurelle·N/A·NCT05257135·150 enrolled

Chronic pain1 trial

The Biopsychosocial Model to Identify Risk Factors for Chronic Postoperative Pain in Orthopedic Trauma Surgery Patients

Not yet recruiting·UUniversity Hospital, Montpellier··NCT07685184·600 enrolled

Epilepsy1 trial

Study of Maternal Pharmacokinetic and Placental Transfer of Levetiracetam

Completed·AAssistance Publique - Hôpitaux de Paris·Preclinical·NCT04117425·14 enrolled

Unspecified1 trial

Development of Clinical and Biological Database

Recruiting·IInstitut du Cancer de Montpellier - Val d'Aurelle·N/A·NCT03449264·4,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Biological collection. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biological collection compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biological collection. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: AAssistance Publique - Hôpitaux de Paris

Biological collection

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2028

Q2 2029

Trials by Indication[1]

Preeclampsia1 trial

CAR1 trial

COVID-191 trial

Imaging1 trial

Stroke1 trial

Brain Injury1 trial

Endometriosis1 trial

Autoimmunity1 trial

Allogeneic Hematopoietic Stem Cell Transplantation1 trial

Cachexia1 trial

Chronic pain1 trial

Epilepsy1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News